Literature DB >> 19733596

Wanted, dead or alive: new viral vaccines.

Ian J Amanna1, Mark K Slifka.   

Abstract

Vaccination is one of the most effective methods used for protecting the public against infectious disease. Vaccines can be segregated into two general categories: replicating vaccines (i.e., live, attenuated vaccines) and non-replicating vaccines (e.g., inactivated or subunit vaccines). It has been assumed that live attenuated vaccines are superior to non-replicating vaccines in terms of the quality of the antiviral immune response, the level of protective immunity, and the duration of protective immunity. Although this a prevalent viewpoint within the field, there are several exceptions to the rule. Here, we will explore the historical literature in which some of these conclusions have been based, including "Experiments of Nature" and describe examples of the efficacy of replicating vaccines compared to their non-replicating counterparts. By building a better understanding of how successful vaccines work, we hope to develop better "next-generation" vaccines as well as new vaccines against HIV--a pathogen of global importance for which no licensed vaccine currently exists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733596      PMCID: PMC2760379          DOI: 10.1016/j.antiviral.2009.08.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  109 in total

Review 1.  Passive antibody therapies: progress and continuing challenges.

Authors:  A Casadevall
Journal:  Clin Immunol       Date:  1999-10       Impact factor: 3.969

2.  The historical feud over polio vaccine: how could a killed vaccine contain a natural disease?

Authors:  M L Meldrum
Journal:  West J Med       Date:  1999-10

3.  Clinical case definitions for Argentine hemorrhagic fever.

Authors:  L H Harrison; N A Halsey; K T McKee; C J Peters; J G Barrera Oro; A M Briggiler; M R Feuillade; J I Maiztegui
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

4.  Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.

Authors:  E E Richie; N H Punjabi; Y Y Sidharta; K K Peetosutan; M M Sukandar; S S Wasserman; M M Lesmana; F F Wangsasaputra; S S Pandam; M M Levine; P P O'Hanley; S J Cryz; C H Simanjuntak
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

5.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

6.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

7.  Investigations on allergic and serological reactions following inoculation of inactivated smallpox vaccines by cutaneous scarification.

Authors:  A Giurcă; V L Topciu; D Voiculescu; E Moldovan; L Plavoşin
Journal:  Virologie       Date:  1976 Jul-Sep       Impact factor: 0.474

Review 8.  Antibodies for the prevention and treatment of viral diseases.

Authors:  L A Sawyer
Journal:  Antiviral Res       Date:  2000-08       Impact factor: 5.970

9.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 10.  Preventing infectious disease with passive immunization.

Authors:  L Zeitlin; R A Cone; T R Moench; K J Whaley
Journal:  Microbes Infect       Date:  2000-05       Impact factor: 2.700

View more
  26 in total

Review 1.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 2.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 3.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 4.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

5.  Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.

Authors:  Andrea Marzi; Peter Halfmann; Lindsay Hill-Batorski; Friederike Feldmann; W Lesley Shupert; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  Science       Date:  2015-03-26       Impact factor: 47.728

6.  Coupling mutagenesis and parallel deep sequencing to probe essential residues in a genome or gene.

Authors:  William P Robins; Shah M Faruque; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

7.  Discovering naturally processed antigenic determinants that confer protective T cell immunity.

Authors:  Pavlo Gilchuk; Charles T Spencer; Stephanie B Conant; Timothy Hill; Jennifer J Gray; Xinnan Niu; Mu Zheng; John J Erickson; Kelli L Boyd; K Jill McAfee; Carla Oseroff; Sine R Hadrup; Jack R Bennink; William Hildebrand; Kathryn M Edwards; James E Crowe; John V Williams; Søren Buus; Alessandro Sette; Ton N M Schumacher; Andrew J Link; Sebastian Joyce
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

Review 8.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

Review 9.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

10.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.